The preprint you linked (https://www.medrxiv.org/content/10.1101/2020.04.08.20054551v1 https://www.medrxiv.org/content/10.1101/2020.04.08.20054551v...) is a hug

The preprint you linked (https://www.medrxiv.org/content/10.1101/2020.04.08.20054551v1 https://www.medrxiv.org/content/10.1101/2020.04.08.20054551v...) is a huge analysis based on historical health records (> 300k per condition). > Worryingly, significant risks are identified for combination users of HCQ+AZM even in the short-term as proposed for COVID19 management, with a 15-20% increased risk of angina/chest pain and heart failure, and a two-fold risk of cardiovascular mortality in the first month of treatment. Based on that, azithromycin would appear to be a decidedly bad choice of antibiotic to use in conjunction with HCQ. Luckily there are many others available. Derek Lowe has a recent and much more detailed analysis of all of this. (https://blogs.sciencemag.org/pipeline/archives/2020/04/11/the-latest-hydroxychloroquine-data-as-of-april-11 https://blogs.sciencemag.org/pipeline/archives/2020/04/11/th...)